Toute l’ingéniosité et la vitalité d’Oncodesign via notre espace ressources

Service

Service
19/10/2021

[CONGRESS] Discovery UK: 26 – 27 October 2021

Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.

Lire la suite
Service
27/09/2021

Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond

Lire la suite
Service
27/09/2021

Animal models for novel therapies on fibrosis and NASH

Lire la suite
Service
04/09/2021

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals

Lire la suite
Service
04/09/2021

Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.

Lire la suite
SOLO-Pharmaco-Imaging
Service
01/07/2021

Oncodesign, Covalab, CheMatech et ABX-CRO lancent DRIVE™-MRT

Découvrez l'alliance d'experts en radiopharmaceutiques : une offre innovante en développement thérapeutique en médecine nucléaire depuis la validation de cibles thérapeutiques, la génération de vecteurs biologiques radiomarqués, l'optimisation de leads, la génération de candidats médicaments jusqu’à l’IND, la conception et le management d'essais cliniques.

Lire la suite
SOLO-Pharmaco-Imaging
Service
Finance
28/06/2021

Oncodesign lance sa nouvelle offre de service DRIVE-MRT™ en partenariat avec Covalab, CheMatech et ABX-CRO

[Communiqué de Presse] L’alliance stratégique pour DRIVE-MRT™ (Molecular RadioTherapy) : ensemble du processus de Drug Discovery spécialisé en radiothérapie systémique ciblée (Théranostique)

Lire la suite
ressources-oncodesign
Service
23/06/2021

[Congress] Microbiome movement Drug Development Summit June 29 – July 1, 2021

Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”

Lire la suite
Service
19/05/2021

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Lire la suite
Service
04/05/2021

[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection

Lire la suite
Service
01/04/2021

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Lire la suite
Service
12/02/2021

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Lire la suite